Models to assess cardiovascular disease (CVD) risk in patients with diabetes often underestimates risk. However, the addition of clinical tests including imaging tests and biomarkers may improve this scenario. It is evident that ECGs can also improve global CVD risk prediction in patients with diabetes and prediabetes, as it can show elevations of strain.
Other imaging modalities such as eye exams and neuropathy assessments have shown a robust change in risk prediction. As compared to general population, which additional tests must be included while predicting CVD risk in diabetic patients?
